James Daniel

About

Highly accomplished, dynamic and results-oriented neuroscientist and drug discovery professional with deep experience driving innovative research in industry and academia. Expertise in biomedical science, preclinical research, biologics discovery, and the development of novel research tools. Proven ability to lead successful cutting-edge multidisciplinary projects and high-performing research teams, foster long-term collaborative relationships, integrate scientific knowledge with strategic development goals, and influence key stakeholders with outstanding communication skills. Dedicated to applying unique skills in research, collaboration and communication to translate fundamental science into meaningful benefits to people’s health.

Employment

• Teva Pharmaceuticals (Australia) Associate Director
  2023 - 2025
• Max-Planck-Institut für Multidisziplinäre Naturwissenschaften Group Leader
  2022 - 2022
• Max Planck Institute of Experimental Medicine Group Leader
  2016 - 2022
• Max Planck Institute for Experimental Medicine Senior postdoctoral scientist
  2013 - 2016
• Children's Medical Research Institute Postdoctoral scientist
  2009 - 2013
• Garvan Institute of Medical Research Postdoctoral scientist
  2008 - 2009

Education

• University of New South Wales Doctor of Philosophy
  2003 - 2008
• University of Newcastle Bachelor of Biomedical Science (Honours I)
  2002 - 2002
• University of Newcastle Bachelor of Biomedical Science
  1999 - 2001

Projects & Funding

Projects & funding information is unavailable.

Publications (22)

• Glutamatergic synaptic resilience to overexpressed human alpha-synuclein
  bioRxiv 2025 DOI: 10.1101/2025.02.06.636960
  +Save
• Highly adaptable deep-learning platform for automated detection and analysis of vesicle exocytosis
  Nature Communications 2025 DOI: 10.1038/s41467-025-61579-3
  +Save
• Highly adaptable deep-learning platform for automated detection and analysis of vesicle exocytosis
  bioRxiv 2024 DOI: 10.1101/2024.08.02.606323
  +Save
• An intellectual-disability-associated mutation of the transcriptional regulator NACC1 impairs glutamatergic neurotransmission.
  Frontiers in molecular neuroscience 2023 DOI: 10.3389/fnmol.2023.1115880
  +Save
• The sulfonadyns: a class of aryl sulfonamides inhibiting dynamin I GTPase and clathrin mediated endocytosis are anti-seizure in animal models
  RSC Medicinal Chemistry 2023 DOI: 10.1039/d2md00371f
  +Save
• A fluorescent nanosensor paint detects dopamine release at axonal varicosities with high spatiotemporal resolution.
  Proceedings of the National Academy of Sciences of the United States of America 2022 DOI: 10.1073/pnas.2202842119
  +Save
• Dopamine imaging
  OSF 2022 DOI: 10.17605/osf.io/ty6uj
  +Save
• A fluorescent nanosensor paint reveals the heterogeneity of dopamine release from neurons at individual release sites
  2021 DOI: 10.1101/2021.03.28.437019
  +Save
• Imaging of Monoamine Neurotransmitters with Fluorescent Nanoscale Sensors
  ChemPlusChem 2020 DOI: 10.1002/cplu.202000248
  +Save
• Response: Commentary: Analysis of SUMO1-conjugation at synapses.
  Frontiers in cellular neuroscience 2018 DOI: 10.3389/fncel.2018.00117
  +Save